51![201 1 to be the target. 2 201 1 to be the target. 2](https://www.pdfsearch.io/img/abd4bb91c49c591d145da96303984318.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English - Date: 2005-07-08 15:14:02
|
---|
52![1 DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH ANTIVIRAL DRUGS ADVISORY COMMITTEE 1 DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH ANTIVIRAL DRUGS ADVISORY COMMITTEE](https://www.pdfsearch.io/img/65f996363f8e320b1c4ee1057bd2235f.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English - Date: 2005-07-08 15:14:03
|
---|
53![Food and Drug Administration Food and Drug Administration](https://www.pdfsearch.io/img/d7d8273c07096d29d144913d195d77a7.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English - Date: 2005-06-20 14:31:16
|
---|
54![DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD[removed]ATTENTION PHARMACIST: Detach DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD[removed]ATTENTION PHARMACIST: Detach](https://www.pdfsearch.io/img/b0ec4cd428d176f9848297e78a58f506.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2009-03-31 14:57:04
|
---|
55![[removed], please? [Slide] Here is an example of a patient who failed without resistance, the single patient in protocol 4 who failed without resistance to any of the [removed], please? [Slide] Here is an example of a patient who failed without resistance, the single patient in protocol 4 who failed without resistance to any of the](https://www.pdfsearch.io/img/ddf2b0af6a649cb0e9fb6af01031dab6.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English - Date: 2007-11-14 15:13:40
|
---|
56![PREZISTA (darunavir) Label PREZISTA (darunavir) Label](https://www.pdfsearch.io/img/9fc9fd6c29f6939f3a92059daa9a5b2c.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2013-11-08 14:29:20
|
---|
57![Darunavir Clinical Pediatric Review Darunavir Clinical Pediatric Review](https://www.pdfsearch.io/img/60f4b46aeb537097437d0d1c12c6e7b1.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|
58![Tipranavir / Protease inhibitors / Pyridines / Organofluorides Tipranavir / Protease inhibitors / Pyridines / Organofluorides](/pdf-icon.png) | Add to Reading ListSource URL: www.fda.govLanguage: English - Date: 2005-05-25 15:52:56
|
---|
59![ABCD Subject: Important Safety Information: Intracranial Hemorrhage in Patients Receiving Aptivus® (tipranavir) capsules Boehringer Ingelheim Pharmaceuticals, Inc. ABCD Subject: Important Safety Information: Intracranial Hemorrhage in Patients Receiving Aptivus® (tipranavir) capsules Boehringer Ingelheim Pharmaceuticals, Inc.](https://www.pdfsearch.io/img/4163b86bf9b2c2eaf70672fdce0be9d1.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|
60![HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PREZISTA safely and effectively. See Full Prescribing Information for PREZISTA. PREZISTA (darunavir) Tablet, Film Co HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PREZISTA safely and effectively. See Full Prescribing Information for PREZISTA. PREZISTA (darunavir) Tablet, Film Co](https://www.pdfsearch.io/img/27eb619870db516b28ec7a99baf5a9e4.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2011-10-25 14:50:21
|
---|